Evidence map›Paper›PMID 36744110›Full record

ArticleFrontiers in artificial intelligence2022

Statistical biopsy: An emerging screening approach for early detection of cancers.

Gregory R Hart, Vanessa Yan, Bradley J Nartowt, David A Roffman, Gigi Stark, Wazir Muhammad, Jun Deng

Open access · goldAbstract read
In one paragraph

Article in Frontiers in artificial intelligence, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Gregory R HartInstitute for Disease Modeling, Global Health Division, Bill and Melinda Gates Foundation, Seattle, WA, United States.
Vanessa YanDepartment of Therapeutic Radiology, Yale University, New Haven, CT, United States.
Bradley J NartowtSMFE, Wright-Patterson Air Force Base, Dayton, OH, United States.
David A RoffmanResearch Partners, Sun Nuclear Corporation (Mirion Technologies Inc.), Melbourne, FL, United States.
Gigi StarkDepartment of Therapeutic Radiology, Yale University, New Haven, CT, United States.
Wazir MuhammadDepartment of Physics, Florida Atlantic University, Boca Raton, FL, United States.
Jun DengDepartment of Therapeutic Radiology, Yale University, New Haven, CT, United States.
Yale University · USFlorida Atlantic University · USGates Foundation · USMirion Technologies (United States) · USWright-Patterson Air Force Base · US

Funding

Medical Research Council MC_PC_17228
6 · The paper itself

Abstract

Despite large investment cancer continues to be a major source of mortality and morbidity throughout the world. Traditional methods of detection and diagnosis such as biopsy and imaging, tend to be expensive and have risks of complications. As data becomes more abundant and machine learning continues advancing, it is natural to ask how they can help solve some of these problems. In this paper we show that using a person's personal health data it is possible to predict their risk for a wide variety of cancers. We dub this process a "statistical biopsy." Specifically, we train two neural networks, one predicting risk for 16 different cancer types in females and the other predicting risk for 15 different cancer types in males. The networks were trained as binary classifiers identifying individuals that were diagnosed with the different cancer types within 5 years of joining the PLOC trial. However, rather than use the binary output of the classifiers we show that the continuous output can instead be used as a cancer risk allowing a holistic look at an individual's cancer risks. We tested our multi-cancer model on the UK Biobank dataset showing that for most cancers the predictions generalized well and that looking at multiple cancer risks at once from personal health data is a possibility. While the statistical biopsy will not be able to replace traditional biopsies for diagnosing cancers, we hope there can be a shift of paradigm in how statistical models are used in cancer detection moving to something more powerful and more personalized than general population screening guidelines.

Indexed as

biopsycancer detectioncancer screeningdata miningindividualized medicinemachine learning and AIneural network

Identifiers

PMID36744110
PMCPMC9895959
OpenAlexW4317627056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.